04:45 PM EDT, 05/31/2024 (MT Newswires) -- Fusion Pharmaceuticals ( FUSN ) said Friday it received a final court order approving the acquisition of the company by a wholly-owned subsidiary of AstraZeneca ( AZN ) .

Under the deal, Fusion shareholders will receive $21 per share in cash upfront plus a deferred payment on the achievement of a future regulatory milestone in the form of a contingent value right of $3.00 a share, the firm said.

The company expects to close the transaction in Q2 this year.

Price: 21.56, Change: +0.04, Percent Change: +0.19